Mineralys Therapeutics (MLYS) announced detailed results from the pivotal Phase 3 Launch-HTN trial in over 1,000 participants ...

Mineralys has reported outcomes from its pivotal randomised, placebo-controlled Phase III Launch-HTN trial assessing ...

Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on RegenXBio (RGNX – Research Report) today and set a price target of $40.00. The company’s shares closed yester ...

Brigadier General Nixon succeeds Kenneth Ehrman, who has served as Chairman since 2020. Mr. Ehrman stepped down from the ...

Does Mineralys Therapeutics, Inc. (MLYS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Detailed price information for Mineralys Therapeutics Inc (MLYS-Q) from The Globe and Mail including charting and trades.

Investing.com -- Mineralys Therapeutics , Inc. (NASDAQ:MLYS) saw its stock jump 2.8% after reporting first quarter 2025 financial results that beat analyst expectations. The clinical-stage ...

May 12, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney ...

Mineralys Therapeutics MLYS is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement. Analysts estimate that Mineralys ...

Mineralys Therapeutics, Inc. announced that it will release its financial results for the first quarter ending March 31, 2025, after the market closes on May 12, 2025. A conference call will take ...

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) saw strong trading volume on Wednesday after HC Wainwright raised their price target on the stock from $30.00 to $42.00.HC Wainwright ...

Mineralys Therapeutics (MYLS) priced an underwritten public offering of ~12.96M shares at a public offering price of $13.50 per share. The aggregate gross proceeds are expected to be ~$175M.